Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda

Trial Profile

Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Sleep disorders
  • Focus Pharmacokinetics
  • Sponsors Biolab Sanus Farmaceutica
  • Most Recent Events

    • 13 Jul 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
    • 13 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Dec 2017.
    • 13 Jul 2017 Planned initiation date changed from 1 Jan 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top